News

The new funding agreement will enable WHO to scale up work on research and development for new antibiotics, antifungals, and non-traditional therapies such as bacteriophages which use viruses to infect and kill bacteria. WHO welcomes this renewed partnership with the European Commission to accelerate efforts to fight AMR by ensuring equitable access to life-saving antimicrobials and diagnostics for people everywhere." Recognizing AMR as a major and growing health threat, WHO and HERA first launched the partnership in 2022 to support the development of new medical countermeasures for tackling AMR and ensure their equitable access. The Organization has also published multiple R&D pipeline assessments in the areas of antibacterials, antifungals and in vitro diagnostics for bacterial and fungal pathogens, respectively, and has advanced work to accelerate optimal approval of priority formulations for pediatric antibiotics. Additionally, WHO has also advanced work on SECURE through a global technical consultation and the development of WHO Country Operational Guidance for introducing antibiotics as well as guidance on policy and regulatory interventions to address antibiotic shortages."